The partnership with Chinese biotech Cellular Biomedicine Group will cost J&J $245 million upfront and give it access to two differentiated CAR-T therapies for diffuse large B-cell lymphoma.
https://www.pharmalive.com/wp-content/uploads/2023/04/BiospaceJNJ4-19-2023.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-05-02 10:55:432023-05-02 10:56:17J&J makes $245M play to develop next-gen CAR-T therapies